Terms: = Ovarian cancer AND CBLC, CBL-3, 23624, ENSG00000142273, RNF57, Q9ULV8, CBL-SL
1 results:
1. Complementary genetic screens identify the E3 ubiquitin ligase cblc, as a modifier of PARP inhibitor sensitivity.
Frankum J; Moudry P; Brough R; Hodny Z; Ashworth A; Bartek J; Lord CJ
Oncotarget; 2015 May; 6(13):10746-58. PubMed ID: 25883215
[TBL] [Abstract] [Full Text] [Related]
